• EACH LIFE IS UNIQUE

We focus on plasma-derived protein therapeutics for treatment of individuals with rare diseases and unmet medical needs.

Kamada has a product line of specialty plasma- derived pharmaceuticals, and is leading in research and development of alpha-1 antitrypsin and specific immunoglobulins.

Watch the video

PRODUCTS

Our proprietary platform technology and know-how allow us to extract and purify injectable protein therapeutics from human plasma.

PIPELINE

Kamada has late-stage plasma-derived protein products in development, focused on orphan indications such as AAT Deficiency, Type-1 Diabetes and Graft-Vs-Host-Disease.

  • Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in adults. It is associated with an increased risk of developing pulmonary emphysema and liver disease, and also skin problems (panniculitis) and vasculitis.

  • The allogeneic transplantation of hematopoietic cells (HCT) is a well-established treatment for hematologic diseases that cannot be cured with conventional treatments.The most common life-threatening complication is Graft Versus Host Disease (GVHD).

  • MORE
    THERAPEUTIC
    FOCUS
    AREAS